Cefamandole nafate (Cefamandole formate sodium)
(Synonyms: 头孢孟多酯钠; Cefamandole formate sodium) 目录号 : GC32123
A prodrug form of cephamandole
Cas No.:42540-40-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Cefamandole nafate is a formate ester prodrug form of the cephalosporin antibiotic cefamandole .1 Cefamandole nafate inhibits the growth of E. cloacae, E. coli, K. pneumoniae, P. mirabilis, P. vulgaris, P. morganii, S. aureus, and S. pyogenes in vitro (MICs = 0.1-50 μg/ml). In vivo, cefamanadole nafate protects against E. cloacae, E. coli, K. pneumoniae, P. mirabilis, P. vulgaris, P. morganii, S. aureus, and S. pyogenes infection in mice (ED50s = 0.3-334 mg/kg). Cefamandole (500 mg/kg) also protects against nephrotoxicity induced by the aminoglycoside antibiotic tobramycin in rats.2
1.Miller, A.K., Celozzi, E., Pelak, B.A., et al.Correlation of in vitro susceptibility with in vivo efficacy in mice for cefoxitin in comparison with cephalosporinsJ. Antimicrob. Chemother.5(5)569-579(1979) 2.Wold, J.S., Turnipseed, S.A., Broddle, W.D., et al.Effect of cefamandole nafate on the toxicity of tobramycinAntimicrob. Agents Chemother.12(4)465-469(1977)
| Cas No. | 42540-40-9 | SDF | |
| 别名 | 头孢孟多酯钠; Cefamandole formate sodium | ||
| Canonical SMILES | O=C(C(N12)=C(CSC3=NN=NN3C)CS[C@]2([H])[C@H](NC([C@H](OC=O)C4=CC=CC=C4)=O)C1=O)[O-].[Na+] | ||
| 分子式 | C19H17N6NaO6S2 | 分子量 | 512.49 |
| 溶解度 | DMSO : ≥ 41 mg/mL (80.00 mM);Water : ≥ 29 mg/mL (56.59 mM) | 储存条件 | Store at -20°C, protect from light, stored under nitrogen |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.9513 mL | 9.7563 mL | 19.5126 mL |
| 5 mM | 0.3903 mL | 1.9513 mL | 3.9025 mL |
| 10 mM | 0.1951 mL | 0.9756 mL | 1.9513 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Conversion of Cefamandole nafate to cefamandole sodium
J Pharm Sci1976 Aug;65(8):1175-8.PMID:10412DOI:10.1002/jps.2600650811.
The rate of hydrolysis of the formyl moiety of Cefamandole nafate was determined as a function of pH, temperature, and concentration of added sodium carbonate or tromethamine. The reaction rate was sensitive to hydroxide ion in the pH 5.5-8.0 range with half-life values of hours to minutes. Hydrolysis was rapid upon the addition of sodium carbonate or tromethamine. Chirality in the 7-D-mandelamido side chain was unaffected by hydrolysis.
Separation and characterization of allergenic polymerized impurities from cephalosporin for injection by trap free two-dimensional high performance size exclusion chromatography × reversed phase liquid chromatography coupled with ion trap time-of-flight mass spectrometry
J Pharm Biomed Anal2018 May 30;154:425-432.PMID:29579634DOI:10.1016/j.jpba.2018.03.043.
As requested by regulatory authorities, polymerized impurities are an important issue of quality control. In this study, we presented the utilization of a trap-free two-dimensional chromatography, which was consisted by a high performance size exclusion chromatography (HPSEC) and a reversed-phase liquid chromatography (RP-LC) coupled to ion trap time-of-flight mass spectrometry with positive mode of electrospray ionization, to separate and characterize ten allergenic impurities in ceftazidime for injection, cefazolin sodium for injection, cefoperazone sodium and sulbactam sodium for injection and Cefamandole nafate for injection. An effective method for characterizing the polymerized impurities in β-lactam antibiotics was established on the basis of column-switching technique which effectively combined the advantages of HPSEC and the ability of RP-HPLC to identify the special impurities. In the first dimension, the column was the Xtimate SEC-120 analytical column (7.8 mm × 30 cm, 5 μm) and the flow rate was 1.0 mL min-1 with gradient elution using 0.005 mol L-1 phosphate buffer solution at pH 7.0 and acetonitrile as mobile phase. In the second dimension, the analytical column was ZORBAX SB-C18 (4.6 × 150 mm, 3.5 μm) using ammonium formate solution (10 mM) and ammonium formate (8 mM) in [acetonitrile-water (4:1, v/v)] solution as mobile phase at a flow rate of 0.4 mL min-1. Eluent associate with each peak separated in the first dimension was trapped by a 20 μL quantitative loop and then transferred (via a six-port valve) into the second dimension system with volatile mobile phase. Through the multiple heart-cutting 2D-LC approach and online desalting technique, the problem of incompatibility between non-volatile mobile phase and mass spectrometry was solved completely. The fragmentation behaviors of ten allergenic impurities were studied. The structures of ten allergenic impurities in cephalosporin drug substance were deduced based on the HPLC-MSn data, in which four impurities were polymerized impurities. The forming factors of polymerized impurity in cephalosporins were also studied.